This study explores the protective effects of Bifidobacterium breve Bif195 (GALENEX™) on aspirin-induced gastrointestinal (GI) damage. The randomized trial, conducted from May 2020 to January 2021 in Denmark, shows that Bif195 significantly reduces ASA-induced gastric mucosal damage compared to a placebo. The odds ratio for this protective effect is 7.2 (p = 0.009). The findings suggest that Bif195 may offer a safe strategy to prevent ASA-related GI adverse events, particularly in the stomach..
Source: https://onlinelibrary.wiley.com/doi/10.1111/apt.17817
